Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 30articles · 30d
- 10+ hour agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 336avg words
- Medical 23
- Health & Wellness 20
- Health 13
- Economy, Business & Finance 11
- Business & Industrial 6
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Noxopharm moves lupus skin therapy toward next human trial
10+ hour, 48+ min ago (292+ words) Noxopharm has announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful and disfiguring skin condition for which no targeted treatment currently exists. The Sydney-based company said the…...
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
5+ day, 7+ hour ago (368+ words) BiotechDispatch Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced…...
US health agency funds broad access trial for Melbourne biotech's ALS drug
5+ day, 8+ hour ago (444+ words) The United States National Institutes of Health has agreed to fund a multimillion-dollar program that will give up to 200 Americans living with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology company Neurizon Therapeutics. The grant,…...
Radiopharm imaging trial offers new hope for pancreatic cancer detection
5+ day, 9+ hour ago (245+ words) Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest to treat forms of cancer. The Sydney-based, dual-listed biopharmaceutical company, which…...
Emyria prepares to open its first Sydney mental health clinic
6+ day, 16+ hour ago (219+ words) Emyria is on the verge of opening its first clinic in Sydney, marking the company's entry into New South Wales and extending its national network of intensive mental health services into Australia's most populous state. The ASX-listed company told investors…...
Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients
1+ week, 13+ hour ago (412+ words) BiotechDispatch Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of…...
Australian biotech Immuron takes gut health treatment to the US market
1+ week, 13+ hour ago (359+ words) BiotechDispatch Australian biotech Immuron takes gut health treatment to the US market Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science company Calmino Group AB....
Telix completes BiPASS enrolment as it pursues a broader role for PSMA PET
1+ week, 4+ day ago (396+ words) Telix Pharmaceuticals has completed enrolment in its pivotal BiPASS trial, moving the Australian company closer to testing whether its gallium-based PSMA PET imaging agents can help determine which men with suspected prostate cancer need a biopsy in the first place....
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
1+ week, 4+ day ago (410+ words) ENA Respiratory has welcomed $2.98 million in funding from Biointelect Venturer to support its first Australian study of INNA-051 in adults with asthma, expanding the clinical program for a once-weekly nasal spray intended to strengthen the body’s early defences against common…...
Cartherics pursues new cell therapy route for cancer and endometriosis
1+ week, 6+ day ago (421+ words) Melbourne company Cartherics is joining forces with the Zucker Institute at the Medical University of South Carolina to investigate whether a novel antibody can strengthen next-generation immune cell therapies for solid tumours and endometriosis. The collaboration will combine Cartherics’ induced…...